| Industry | 科学研究和技术服务业 | ||||||||||||||||||||||||
| Company Introduction | 新疆百花村医药集团股份有限公司始于1959年，1996年在上海证券交易所上市，股票代码：600721，注册地位于新疆五家渠市。主要从事医药研发、临床试验、检测分析、商业物业等业务。包括以药学研发为主的华威医药，以临床试验为主的礼华生物、以分析检测业务为主的西默思博以及商业物业管理等共计12家子分公司。 公司在乌鲁木齐拥有4.6万平方米的商业综合体大厦，在南京拥有2栋面积为3万平方米左右的办公研发大楼。拥有完善的国际先进的药物研究仪器设备和研发管理体系，在全国主要城市布局了多个临床研究中心。以多名博士硕士为核心的技术骨干和研发管理团队，致力于小分子化学原料药和高端制剂开发、药物质量研究、临床研究、分析检测以及研发注册申报，取得了骄人的研究成果。公司可为合作伙伴提供新药仿制药开发一站式全流程服务。 | ||||||||||||||||||||||||
| Main Business | 药物发现、研究、技术服务，提供从药物发现、CMC、临床CRO、药品注册、CMO/API供应等新药开发全流程的服务及一体化的解决方案。 | ||||||||||||||||||||||||
| Legal Representative | 郑彩红 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | -- | ||||||||||||||||||||||||
| Solicitors | 北京市时代九和律师事务所 | ||||||||||||||||||||||||
| Auditors | 致同会计师事务所（特殊普通合伙）;希格玛会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0991-2356610;0991-2356632;0991-2356600;0991-2356608 | ||||||||||||||||||||||||
| Fax No | 0991-2356601 | ||||||||||||||||||||||||
| Website | www.xjbhc.net | ||||||||||||||||||||||||
| bhc@xjbhc.org | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 26/06/1996 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.034 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 1.851 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 2.245B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |